retatrutide weight loss efficacy safety trial results First phase 3 data, a Triumph of Science! Weight-loss medicine continues to evolve. – Retatrutide (LY-3437943) Market Analysis, 2033:

For type 2 diabetes (NICE NG28), GLP-1 receptor agonists are generally considered after metformin-based therapy has proven insufficient, and can be initiated in primary care according to local formularies and prescribing arrangements

Kardashian states that she spent five years collaborating with doctors and scientists to develop her supplement line using clinically-backed ingredients

da Silva, Implications of GLP-1 agonist use on airway management, Am

Contemporary Cardiology

Like many chronic diseases, obesity has a wide range of causes and drivers, including those related to genetics, sociocultural factors, mental health, ultra-processed foods, economics, commercial determinants, and environmental factors